This study identified drug-associated OA reporting signals in FAERS and prioritized candidate genes that warrant further validation that should be interpreted as hypothesis-generating rather than as evidence of causal relationships, confirmed molecular mechanisms, or validated diagnostic biomarkers.
Abstract
Objective
To identify drugs disproportionately reported with osteoarthritis (OA) in the FDA Adverse Event Reporting System (FAERS) and to prioritize candidate molecular features for further validation.
Methods
FAERS reports from the first quarter of 2004 to the first quarter of 2025 were analyzed. Disproportionality analysis was performed using the reporting odds ratio and bayesian confidence propagation neural network methods. Sensitivity analyses were conducted using alternative lower-bound thresholds for the reporting odds ratio confidence interval. Least absolute shrinkage and selection operator regression was applied as an exploratory feature-refinement method. Time-to-onset (TTO) and Weibull shape parameter analyses were performed to describe temporal reporting patterns. Drug-related genes were integrated with OA transcriptomic data, followed by functional enrichment, protein-protein interaction network analysis, and machine-learning-based candidate-gene prioritization.
Results
Pharmacovigilance analysis identified 18 drugs or fixed-dose combinations with drug-associated OA reporting signals. Among 2964 of 18,175 OA reports (16.3%) with complete and valid date information, the median TTO was 245 days (Q1-Q3: 29-789 days). Weibull shape parameter analysis yielded a β value of 0.524 (95% CI: 0.509-0.539), indicating an early-failure reporting pattern. Transcriptomic analysis identified 80 OA-related pharmacovigilance-related genes. Subsequent exploratory network and machine-learning analyses prioritized CP and RUNX1 as candidate genes for further investigation.
Conclusion
This study identified drug-associated OA reporting signals in FAERS and prioritized candidate genes that warrant further validation. These findings should be interpreted as hypothesis-generating rather than as evidence of causal relationships, confirmed molecular mechanisms, or validated diagnostic biomarkers.
Findings in this study may support pharmacovigilance surveillance and hypothesis generation, but should be interpreted as reporting associations rather than evidence of causality.
Kai Liu, Xiao-Hu Yang, Ling-Ti Kong· Frontiers in Pharmacology· 0 citations
Objectives This real-world study aimed to identify pharmacovigilance signals for congenital heart disease (CHD) associated with drugs exposure and to characterize the phenotypic spectrum of CHD adverse event reports. Methods Adverse event reports for drug potentially associated with CHD were collected from the US Food...
Chun-Lin He, Xiao-Nan Zhang, Gui-Xin Zhao et al.· American Heart Journal Plus:...· 2 citations
Background Cachexia is a devastating metabolic syndrome that has a profound impact on survival rate and quality of life. Currently, there is still a scarcity of systematic evidence regarding drug-induced cachexia. This study aims to identify drugs associated with cachexia through the first large-scale pharmacovigilance...
Ling-Li Huang, Shu-Chen Dong, Quan-Li Zhang et al.· Frontiers in Pharmacology· 0 citations
Fruquintinib is characterized by a higher proportion of early-onset and potentially unlabeled adverse events, highlighting the need for early and tailored safety monitoring in clinical practice.
Bing Wu, Xin-Ning Yu, Hua-Tao Wu et al.· Journal of Gastrointestinal...· 0 citations
ABSTRACT Tocilizumab, a humanized monoclonal antibody targeting the interleukin-6 receptor, is widely used in immune-mediated diseases, yet its real-world safety in pediatric populations remains insufficiently characterized. This retrospective pharmacovigilance study analyzed adverse event (AE) reports from the U.S. Fo...
Gang Wu, Xue-Qing Ma, Bin Zhu et al.· Human Vaccines & Immunothera...· 1 citation